Fresenius Medical Care Q4 and FY2025 results: Strong recovery, but what about 2026?

Fresenius Medical Care’s share price weakness may make investors think something is wrong with the business.

But when I look at the numbers, that is not really the case.

In fact, Fresenius Medical Care’s Q4 2025 results were strong, and FY2025 was clearly better than FY2024. The real issue is not whether the business improved. It did. The bigger question is whether that momentum can continue into 2026 as some tailwinds fade and new investments start to weigh on profits.

That is where the real debate is.

Before we go further, a quick disclaimer: I am a shareholder of Fresenius Medical Care, so this is not investment advice. This is how I think through the business as an investor.

Fresenius Medical Care Q4 2025 results: What happened?

Let’s start with the latest quarter.

In Q4 2025, Fresenius Medical Care reported revenue of around €5.07 billion. On the surface, that looked flat year-on-year. But that number does not tell the full story. At constant currency, revenue grew 7%, while organic growth was 8%.

More importantly, profits improved sharply.

Adjusted operating income rose 44% to €705 million, and adjusted operating margin expanded from 9.6% to 13.9%. Adjusted earnings per share also jumped strongly. So this was not just a decent quarter. It was a quarter that showed real operational progress.

For a business like Fresenius Medical Care, that matters.

This is not a flashy, high-growth story where investors care only about top-line expansion. Dialysis is a more operational business. What matters is whether the company can improve reimbursement mix, manage costs, protect margins, and turn a stable healthcare platform into stronger earnings and cash flow.

And in Q4 2025, that is exactly what happened.

The biggest improvement came from the Care Delivery segment, especially in the U.S. This part of the business benefited from favourable reimbursement dynamics, better payor and rate mix, pharmaceutical-related income, and continued savings from the company’s transformation program.

That said, investors should not simply assume that every part of this quarter is fully repeatable.

Some of the strength came from tailwinds that may be weaker in 2026. So while the quarter was genuinely good, the more important job for investors is to separate what is sustainable from what is temporary.

Subscribe to our newsletter if you enjoy insights like this.

Fresenius Medical Care FY2025 results vs FY2024

If we zoom out from one quarter and look at the full year, the improvement becomes even clearer.

FY2025 was a better year than FY2024 for Fresenius Medical Care.

Revenue increased to €19.63 billion from €19.34 billion in FY2024. Organic growth improved from 4% in 2024 to 8% in 2025. Adjusted operating income increased from around €1.81 billion to €2.21 billion, while adjusted operating margin improved from 9.3% to 11.3%.

That is meaningful progress.

This tells me the improvement in Fresenius Medical Care was not just a one-quarter story. The company became more profitable across the full year, and that matters much more than short-term market noise.

In simple terms, Fresenius Medical Care in 2025 became a stronger business than it was in 2024.

It was more profitable.

It generated more cash.

It reduced leverage.

And it improved shareholder returns.

Operating cash flow rose to €2.68 billion from €2.39 billion in 2024. Free cash flow also improved. Net debt and lease liabilities fell to around €9.2 billion, while leverage improved to 2.5x, down from 2.9x at the end of 2024.

On top of that, the company repurchased shares and proposed a slightly higher dividend.

So when I compare Fresenius Medical Care FY2025 vs FY2024, the conclusion is quite straightforward: 2025 was a year of genuine recovery and stronger execution.

Want a concise version of Charlie Munger’s 25 human misjudgements? Download here!

Why did the market still react cautiously?

Because the market is always looking forward.

And when Fresenius Medical Care gave its 2026 outlook, the tone was more cautious than investors had hoped.

Management said revenue in 2026 is expected to be broadly flat, while operating income is expected to stay around a similar level, within a range of negative to positive mid-single-digit percentage change versus 2025.

That is not a disaster.

But it is also not the kind of guidance that gets investors excited after such a strong year.

So the market’s reaction was less about Q4 2025 being weak and more about 2026 not looking strong enough to sustain the same level of optimism.

Fresenius Medical Care 2026 outlook: Risks, drivers and what to watch

To me, 2026 looks like a transition year for Fresenius Medical Care.

Not a broken year.

Not a collapse.

But a year where the company has to protect the gains it made in 2025 while investing for the next phase of growth.

Risks for Fresenius Medical Care in 2026

The first risk is that some of the benefits that helped in 2025 will start to fade.

In 2025, Fresenius Medical Care benefited from reimbursement-related tailwinds, including TDAPA. Those were helpful. But management has already said some of these benefits will phase out in 2026.

The second risk is inflation.

Like many healthcare businesses, Fresenius Medical Care still faces pressure from labour costs and other operating expenses. Even if the business remains stable, cost inflation can still eat into margins if not managed carefully.

The third risk is that the company is investing more aggressively.

Management highlighted strategic investments tied to the 5008X CARE system rollout in the U.S. and broader IT upgrades. These investments may be the right long-term move, but in the near term, they create cost pressure.

That means 2026 could look softer, not because the business is weakening, but because the company is spending today to support future improvements.

Subscribe to our newsletter if you enjoy insights like this.

Drivers for Fresenius Medical Care in 2026

On the positive side, there are still real drivers in the business.

One of the most important is the 5008X rollout in the U.S. Management described this as the biggest clinic infrastructure transition in the company’s history. The goal is to replace around 20% of the installed base in its own U.S. clinics during 2026.

That may create near-term expense pressure, but the long-term goal is clear: better patient outcomes, better efficiency, and a stronger competitive position.

Another driver is continued operational discipline.

Fresenius Medical Care has already shown that it can improve margins and reduce costs through its transformation program. If management continues to execute well, that can help offset some of the headwinds in 2026.

There is also an important nuance around Value-Based Care. Management said revenue in this part of the business could face a headwind due to changes in risk contracting and revenue recognition. That could make the top line look weaker. But that does not necessarily mean the economics of the business are getting worse.

That is why investors need to look beyond headline revenue and focus on margins, cash flow, and execution quality.

Final thoughts on Fresenius Medical Care

My read is quite simple.

The recent weakness in sentiment does not automatically mean the business is deteriorating. In fact, the numbers suggest the opposite. Fresenius Medical Care has made real progress.

But after a strong 2025, expectations were higher. And with 2026 shaping up as a transition year, the market is now resetting those expectations.

So the real investment question is no longer whether Fresenius Medical Care had a good quarter.

It did.

The real question is whether management can turn this transition period into a stronger business in 2027 and beyond.

And that is where the investment debate should be.